Ashis Roy (TCGLS Member), Dr. Mrinalkanti Kundu (TCGLS Member), Dr. Pranab Dhar (TCGLS Member), Arnish Chakraborty (TCGLS Member), Dr. Soumen Mukherjee (TCGLS Member), Jayatri Naskar (TCGLS Member), Dr. Chhanda Rarhi (TCGLS Member), Dr. Rajib Barik (TCGLS Member), Dr. Susanta Kumar Mondal (TCGLS Member), Mushtaq Ahmad Wani, Rahul Gajbhiye, Prof. Kuldeep K. Roy, Dr. Arup Maiti (TCGLS Member), Priyadarshi Manna (TCGLS Member), Prof. Susanta Adhikari
A series of novel bicyclic, substituted pyrimidinone compounds were designed, synthesized, and characterized. In vitro anti‐proliferative activity of the synthesized compounds was evaluated against six different human cancer cell lines using MTT assay. Among all twenty-four compounds tested, compound 22 (N‐([1,1′‐biphenyl]‐4‐yl)‐2‐((3‐methyl‐4‐oxo‐6,7,8,9‐tetrahydro‐4Hpyrido[1,2‐a]pyrimidin‐2‐yl)oxy)acetamide) exhibited significant cell growth inhibition of human liver cancer cells HepG2 with GIC50 (50% growth inhibitory concentration) value of 120+10 nM and was found to be selective over healthy human embryonic kidney (HEK) cell line (33.1% inhibition at 20 μM). Further studies demonstrated that compound 22 induced cell apoptosis in HepG2 cells and resulted in a similar effect to Staurosporine, a well known proapoptotic compound widely used to induce apoptosis in various cancer cell lines. Compound 22 also rendered acceptable aqueous solubility (3.5+0.37 μM, at pH 7.4) and attractive metabolic stability against human liver microsomes with a half‐life of 34.63+0.33 minutes. Based on the similarity observed between the known tankyrase‐1 inhibitors available in the literature and compound 22, in silico docking study was performed and the results suggested that the compound interacted with the key amino acid residues present in the tankyrase‐1 enzyme active site.